Development of an HIV Rev-dependent dual-reporter cell for anti-HIV drug screenin

开发用于抗 HIV 药物筛选的 HIV Rev 依赖性双报告细胞

• 批准号: 8138239
• 负责人: YUNTAO WU
• 金额: $ 7.1万
• 依托单位: GEORGE MASON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-05 至 2013-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8138239
• 关键词: AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Anti-Retroviral Agents; Antibodies; Biological Assay; CCR5 gene; Cell Line; Cells; Chemicals; Dependency; Development; Exhibits; Flow Cytometry; Gene Expression; Grant; HIV; HIV Antibodies; HIV Infections; HIV Long Terminal Repeat; Hela Cells; Highly Active Antiretroviral Therapy; Immune; In Vitro; Inhibitory Concentration 50; Lactamase; Lentivirus Vector; Libraries; Long Terminal Repeats; Luciferases; Measures; Mediating; Methodology; Mitogens; Multi-Drug Resistance; Mutation; Noise; Pharmaceutical Preparations; Preclinical Drug Evaluation; Probability; Reagent; Reporter; Reporter Genes; Reporting; Research; Research Methodology; Response Elements; Screening procedure; Signal Transduction; Suspension substance; Suspensions; System; Technology; Testing; Transcriptional Activation; Translations; United States National Institutes of Health; Up-Regulation; Ursidae Family; Viral; Viral Load result; Virus; base; cytokine; cytotoxicity; drug candidate; drug discovery; high throughput screening; inhibitor/antagonist; novel; novel therapeutics; nucleocytoplasmic transport; pandemic disease; programs; promoter; prospective; repository; tat Protein; transcription factor; treatment planning

DESCRIPTION (provided by applicant): HIV/AIDS is a worldwide pandemic afflicting 40 million people, and currently there is no cure. The proposed research is to develop a new reporter cell line to facilitate the discovery of novel anti-HIV drugs. This prospective reporter cell system will employ a Rev-dependent lentiviral vector, which has been shown previously to be highly specific to HIV infection. This novel system will greatly facilitate the development of a novel cell- based drug screening platform. Additionally, by employing two reporters this system can be used in multiple assay formats and would be amenable to high-throughput screens for antiretroviral compounds. PUBLIC HEALTH RELEVANCE: This NIH R03 Small Research Program grant is to develop a new research methodology, namely, the development of a new Rev-dependent cell line to screen for anti-HIV drugs. HIV infection causes AIDS that afflicted approximately 40 million people globally. This proposed research will facilitate the development of new therapeutics.

描述（由申请人提供）：艾滋病毒/艾滋病是一种世界性的流行病，折磨着4000万人，目前还没有治愈方法。这项研究旨在开发一种新的报告细胞系，以促进新型抗HIV药物的发现。该前瞻性报告细胞系统将采用Rev依赖性慢病毒载体，该载体先前已被证明对HIV感染具有高度特异性。这一新的系统将极大地促进基于细胞的新型药物筛选平台的开发。此外，通过使用两个报告基因，该系统可以用于多种测定形式，并且可以用于抗逆转录病毒化合物的高通量筛选。 公共卫生关系：NIH R 03小型研究项目资助将开发一种新的研究方法，即开发一种新的Rev依赖性细胞系来筛选抗HIV药物。艾滋病毒感染导致艾滋病，全球约有4 000万人感染艾滋病。这项拟议的研究将促进新疗法的开发。